Class / Patent application number | Description | Number of patent applications / Date published |
424432000 | IUD or ring | 38 |
20080199511 | Sustained Release Compositions Containing Progesterone Receptor Modulators - Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions. | 08-21-2008 |
20080206310 | Regimens for Controlled Drug Delivery Devices for Contraception - The subject invention provides for new regimens for contraceptive dosage forms. | 08-28-2008 |
20080286339 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 11-20-2008 |
20090060982 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 03-05-2009 |
20090123522 | Medicament Delivery Device and a Method of Medicament Delivery - A medicament delivery device and method of delivering a medicament is provided wherein the device is insertable into the uterine myometrium for the delivery of medicaments to the pelvic area and organs thereof, for example, the bladder, peritoneum, the vulva, vagina, fallopian tubes, ovaries, and uterus, and then to the bloodstream. | 05-14-2009 |
20090202612 | Monolithic Intravaginal Rings Comprising Progesterone and Methods of Making and Uses Thereof - The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid. | 08-13-2009 |
20090291120 | Hydrophilic Polyurethane Compositions - A water-swellable linear polymer is made by reacting together a polyethylene oxide of number average molecular weight less than 4,000, an aliphatic diol, and a difunctional diisocyanate. Controlled release composition comprises the polymer together with an active agent. The polymer is able to take up pharmaceutically active agents of molecular weight 200 to 20,000. | 11-26-2009 |
20090311306 | Intrauterine contraceptive device - An intrauterine contraceptive device comprising a carrier body ( | 12-17-2009 |
20090324692 | Polyurethane Elastomers - A linear polymer is obtained by reacting together a polyethylene glycol or polypropylene glycol; a PEG-PPG-PEG or PPG-PEG-PPG block copolymer; a difunctional amine or diol; and a diisocyanate. A controlled release composition comprises the polymer together with an active agent. Active agents of molecular weight 200 to 20,000 may be used. | 12-31-2009 |
20100040671 | Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof - The present invention relates to intravaginal devices having a rigid support, methods of making, and uses thereof. The devices comprise (a) a rigid support having a Shore A Hardness of at least about 20 and a tensile strength of at least about 1 MPa, (b) a matrix, and (c) an active agent dispersed in the matrix, wherein the support and the matrix are adjacent and wherein the device is annular. | 02-18-2010 |
20100062039 | Intravaginal Ringed Mesh Device And Applicator Therefor - This invention generally covers a ringed-mesh intravaginal device and applicator therefore wherein the ringed-mesh comprises a composite ring comprising a flexible matrix containing one or more bioactive agent or agents and needed excipients or modulators, and the said matrix is reinforced with a fibrous construct to provided needed initial and in-use biomechanical stability. Of special application of the medicated, ringed-mesh is its use for securing contraception relying on biomechanical, pharmacological, and biochemical means. | 03-11-2010 |
20100129425 | VAGINAL DELIVERY SYSTEM FOR MIRTAZAPINE - This invention relates to an extended release formulation comprising solid mirtazapine, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing mirtazapine. The polymer is preferably made of ethylene-vinyl acetate copolymer. | 05-27-2010 |
20100136090 | Helically-Shaped Drug Delivery System - The present invention relates to a helically-shaped medicated veterinary system suitable for delivery of a drug to the vaginal cavity of a female non-human mammal and to a method of manufacture. The drug delivery system is helically-shaped and comprises a three layered polymer fibre. The polymer fibre comprises a polymer core, a polymer intermediate layer comprising a drug, and a polymer skin. The medicated system provides a controlled delivery of drug to the vaginal cavity of the mammal. The present invention also relates to a process of making the springs. | 06-03-2010 |
20100203104 | DELIVERY SYSTEM FOR RISPERIDONE - This invention relates to an extended release formulation comprising solid risperidone, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing risperidone. The polymer is preferably made of ethylene-vinyl acetate copolymer. | 08-12-2010 |
20100285097 | VAGINAL DELIVERY SYSTEM - The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance. | 11-11-2010 |
20110020423 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION - Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors. | 01-27-2011 |
20110033519 | Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use - The invention provides a device and a compound for the prevention and/or treatment of uterine fibroids in human patients, wherein the compound is dispensed from the device and is administered locally to the uterine tissue. | 02-10-2011 |
20110097382 | METHODS AND KITS FOR REDUCING THE LIKELIHOOD OF IMPLANTATION FAILURE AND PREGNANCY-RELATED DISORDERS IN RECIPIENTS OF ARTIFICIAL INSEMINATION - Methods and kits for preventing or reducing the likelihood of implantation failure and pregnancy-related disorders in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF). | 04-28-2011 |
20110212155 | Flexible, Compressed Intravaginal Rings, Methods of Making and Using the Same, and Apparatus for Making the Same - The present invention is directed to flexible, compressed intravaginal rings comprising a substantially homogeneous compressed mixture comprising a polymethacrylate, a plasticizer, and an active agent, and methods of making and using the same, and apparatus for making the same. | 09-01-2011 |
20110236462 | INTRAVAGINAL DRUG DELIVERY DEVICE - Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female. | 09-29-2011 |
20130209539 | CORE SHEATH DRUG DELIVERY DEVICES - It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation. | 08-15-2013 |
20130266632 | DRUG DELIVERY SYSTEM BASED ON POLYETHYLENE VINYLACETATE COPOLYMERS - A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby,
| 10-10-2013 |
20130315974 | Non-Hormonal Female Contraceptive - Disclosed herein are compositions and methods for controlling fertility of a female subject. Particularly exemplified are compositions comprising sugar derivatives, such as 2-deoxyglucose, D-mannoheptulose; and/or 5-thio-D-glucose. Also disclosed herein are methods of preserving ova supply in a female subject that involves administering glucose derivatives. The composition typically includes a glucose derivative that affects Foxo3a expression. | 11-28-2013 |
20140004171 | TREATMENT OF ENDOMETRIOSIS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL AGENT | 01-02-2014 |
20140030313 | TREATMENT OF MENSTRUAL PAIN AND EXCESSIVE MENSTRUAL BLOOD LOSS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUG - A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering intravaginally to the female a first therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) that relieves menstrual pain and a second therapeutically effective amount of an active agent that reduces menstrual blood loss, wherein the NSAID and the active agent are simultaneously administered by the same drug delivery device, wherein the active agent is any one of an antifibrinolytic agent and a hemostatic agent. | 01-30-2014 |
20140044769 | COMPOSITE ABSORBABLE/BIODEGRADABLE RINGS FOR CONTROLLED DRUG DELIVERY - A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer. | 02-13-2014 |
20140056961 | PLATINUM-CATALYZED INTRAVAGINAL RINGS - The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of an antimicrobial compound, e.g., Dapivirine, to a human. The intravaginal rings of the invention address previous stability issues by utilizing a platinum catalyst (e.g., in the form of a platinum-siloxane complex) for the cross-linking reaction. The vaginal rings surprisingly achieve relatively high and steady release rates in vivo with a matrix ring containing a relatively small loading dose. While the matrix rings of the present invention have in vivo the steady release rates associated with reservoir rings, they are easier and less expensive to manufacture. The present invention also provides methods of blocking DNA polymerization by an HIV reverse transcriptase enzyme, methods of preventing HIV infection in a female human, methods of treating HIV infection in a female human, and methods of preparing platinum-catalyzed intravaginal rings. | 02-27-2014 |
20140056962 | DRUG DELIVERY SYSTEM - The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with crystals of the second (pharmaceutically) active compound. | 02-27-2014 |
20140099356 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION - Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors. | 04-10-2014 |
20140302115 | DRUG DELIVERY SYSTEM BASED ON POLYETHYLENE VINYLACETATE COPOLYMERS - A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby,
| 10-09-2014 |
20150306230 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF - A drug delivery vehicle (e.g., a patch, a pill, an intravaginal ring, and an implant) may include a polymer matrix comprising a plasticizer and at least one selected from the group consisting of: a cellulose ester, a cellulose ether, a starch ester, a starch ether, and a combination thereof. A drug may be dispersed in the polymer matrix, in another portion of the drug delivery vehicle, or both. | 10-29-2015 |
20150320766 | COPPER INTRAUTERINE DEVICE - The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects. | 11-12-2015 |
20150320820 | MICROBIOCIDES FROM PLANT EXTRACTS FOR PROTECTION AGAINST HSV 2 INFECTION - Disclosed herein is a microbicidal composition comprising combination of selected extracts of aerial parts of plants such as | 11-12-2015 |
20150328319 | VAGINAL RING INCLUDING MELOXICAM AND AN AGENT FOR MODULATING THE RELEASE OF THE ACTIVE PRINCIPLE, WHICH CAN BE USED AS A CONTINUOUS-USE CONTRACEPTIVE IN WOMEN - The invention relates to a sustained-release vaginal ring which includes meloxicam and an agent for modulating the release of the active principle, such as polyvinylpyrrolidone K-30, which releases the active principle over at least 90 days and which can be used as a continuous-use contraceptive in women. The vaginal ring preferably includes 5 wt % to 30 wt % of meloxicam, relation to total weight of the formulation. | 11-19-2015 |
20160000706 | Core Sheath Drug Delivery Devices - It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation. | 01-07-2016 |
20160000797 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS - The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual. | 01-07-2016 |
20160089380 | PROGESTERONE IMPREGNATED VAGINAL RING/PESSARY - A progesterone impregnated vaginal ring/pessary includes a circumferential outer ring composed of a progesterone impregnated biomaterial, wherein the outer ring has a substantially circular configuration while lying flat with an outer diameter of 60 mm to 70 mm and a thickness of approximately 5 mm. The vaginal ring/pessary also includes a transparent membrane extending along an interior space defined by the outer ring. The transparent membrane is composed of a silicone polymer, has a thickness of 1 mm to 3 mm, and includes a plurality of apertures, which are 4 mm to 5 mm in diameter, circumferentially spaced about a perimeter of the transparent membrane. | 03-31-2016 |
20160184493 | PARTIALLY ABSORBABLE FIBER-REINFORCED COMPOSITES FOR CONTROLLED DRUG DELIVERY - This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mechanical properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biological site; this can be a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop or subcutaneous tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment. | 06-30-2016 |